The Greater Cannabis Company, Inc. (GCAN)
| Market Cap | 2.26M |
| Revenue (ttm) | 50,284 |
| Net Income (ttm) | -1.66M |
| Shares Out | 84.17M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $0.0062 |
| Previous Close | $0.0047 |
| Change ($) | 0.0020 |
| Change (%) | 31.92% |
| Day's Open | 0.0050 |
| Day's Range | 0.0048 - 0.0115 |
| Day's Volume | 332,323,324 |
| 52-Week Range | 0.0018 - 0.0371 |
News
There are no news available yet.
About GCAN
The Greater Cannabis Company, a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. The company intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer product, and pharmaceutical companies in the legal cannabis and CBD industries to bring the product to the North American market in legal medical and recreational cannabis and CBD segments. The Greate... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | |
| CEO Aitan Zacharin | Employees 2 |
| Stock Exchange OTCMKTS | Ticker Symbol GCAN |
Financial Performance
In 2019, GCAN's revenue was $7,120, a decrease of -92.53% compared to the previous year's $95,375. Losses were -$1.65 million, 96.5% more than in 2018.